To the best of our knowledge, this is the first study to provide information about feasibility and tolerability of the combination cisplatin/gemcitabine in the adjuvant treatment of NSCLC.

Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...

Pancreatic cancer is the fourth leading cause of cancer death in the US, with over 35,000 deaths reported in 2009. 1 In 1997, gemcitabine became the standard of care for advanced disease and since ...

Novocure this week announced positive topline results from its Phase 3 trial of its Tumor Treating Fields for pancreatic cancer.

Background: The combination cisplatin/gemcitabine is one of the most active and well-tolerated regimens in advanced non–small-cell lung cancer (NSCLC). We undertook this pilot study to evaluate ...

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer ...